Many pathogens are sheltered from host immunity by surface polysaccharides that would be ideal as vaccines except that they are too similar to host antigens to be immunogenic. The production of functional IgG is a desirable response to vaccines; because IgG is the only isotype that crosses the placenta, it is of particular importance in maternal vaccines against neonatal disease due to group B Streptococcus (GBS). Clinical studies found a substantially lower proportion of IgG-relative to IgM-among antibodies elicited by conjugates prepared with purified GBS type V capsular polysaccharide (CPS) than among those evoked by CPSs of other GBS serotypes. The epitope specificity of IgG elicited in humans by a conjugate prepared with type V CPS is for chemically desialylated type V CPS (dV CPS). We studied desialylation as a mechanism for enhancing the ability of type V CPS to induce IgM-to-IgG switching. Desialylation did not affect the structural conformation of type V CPS. Rhesus macaques, whose isotype responses to GBS conjugates match those of humans, produced functionally active IgG in response to a dV CPS-tetanus toxoid conjugate (dV-TT), and 98% of neonatal mice born to dams vaccinated with dV-TT survived lethal challenge with viable GBS. Targeted chemical engineering of a carbohydrate to create a molecule less like host self may be a rational approach for improving other glycoconjugates.
C apsular polysaccharides (CPSs) dominate the surface of some bacteria and are the major target of the immune system's attack, which primarily involves antibodies, complement, and phagocytic cells. CPSs are considered T cell-independent antigens; their use in vaccines has been optimal only with protein-carrier chemical conjugation, which elicits T cell help for B cells recognizing the carbohydrate, with consequent isotype switching from IgM to IgG (1) . Successful glycoconjugate vaccines have been developed against Haemophilus influenzae type b (2) and several serogroups of Streptococcus pneumoniae (3) and Neisseria meningitidis (4) . However, the human immune system sometimes fails to mount an adaptive immune response to microbial CPS because of great structural similarity of the CPS to the host's own cells. For example, the ␣-2,8-linked sialic acid homopolymeric capsule of serogroup B meningococci structurally resembles saccharides on human neural cell adhesion molecules (5) and oligosaccharides on fetal tissues (6) . Likewise, the hyaluronic acid capsule of group A Streptococcus is identical to carbohydrate structures on human tissue (7) . Humans do not respond with antibodies to these two molecules, presumably because such a response would generate autoimmunity.
Group B Streptococcus (GBS) is a major cause of serious infection in neonates and the elderly (8) . Of the 10 identified serotypes (9, 10) , five (Ia, Ib, II, III, and V) are commonly associated with human disease. Antibodies to the CPSs of these serotypes are protective against neonatal infection and are acquired by the neonate through transplacental passage of CPS-specific IgG (11) . After conjugation to a carrier protein, CPSs of types Ia, Ib, II, and III induce strong IgG responses in humans (12) ; type III conjugate vaccine induces maternal IgG that crosses the placenta and persists in the newborn for at least 2-3 months-the period of maximal susceptibility (13) .
A striking difference between human antibody responses to glycoconjugates prepared with type V CPS and those prepared with type II or III CPS [supporting information (SI) Table S1 ] or with type Ia or Ib CPS (data not shown) is the ability of the latter four vaccines to induce mainly IgG and relatively less IgM; in contrast, vaccines prepared with type V CPS induce higher concentrations of specific IgM relative to IgG. Uncoupled type V CPS vaccine also induces higher levels of IgM relative to IgG in healthy adults (Table S1 ). IgG responses are desirable in most cases because of the long-term production and durability of this isotype. In GBS vaccines, in which maternal antibodies must cross the placenta to provide protection against neonatal disease, strong IgG responses are essential.
We hypothesized that the predominantly IgM response of human recipients to type V CPS-based vaccines is due to structural similarities between the sialic acid-dominated epitopes on this CPS and those found on host glycoproteins. We report that human antibodies induced by a type V CPS conjugate vaccine poorly recognize the trisaccharide side chain that terminates with sialic acid on the type V CPS heptasaccharide repeating unit (RU)-a result suggesting that, unlike that on type III CPS, the sialic acid on type V CPS does not exert conformational control of the dominant antigenic epitope. Removal of sialic acid residues results in a type V CPS antigen for which these antibodies exhibit high specificity; the implication is that the terminal sialic acid residue of the RU is not essential for antibody recognition. In other clinically important GBS CPSs (Ia, II, III), the sialic acid residue influences recognition of specific protective antibody (14) (15) (16) (17) .
These results provided the rationale for the creation of a novel GBS type V conjugate with CPS lacking terminal sialic acid residues. The desialylated type V (dV) CPS-tetanus toxoid vaccine (dV-TT) induces type-specific and functional antibody that is predominantly of the IgG isotype in nonhuman primates and outbred mice. Presentation of the immunodominant epitope on a complex carbohydrate to the immune system by the unmasking (i.e., elimination) of epitopes offers a new approach to the design of vaccines targeting carbohydrate moieties.
Priming the immune system with antigens that have been slightly modified from those native to the pathogen is a time-tested strategy for development of highly effective vaccines. Although most modifications have involved protein antigens such as toxins, alterations of carbohydrate moieties, such as N-acetylneuraminic acid on tumor cells (18) and CPSs from encapsulated bacteria, have also enhanced the immune response to those targets. To our knowledge, this is the first report of a shift induced in the mammalian antibody class response by the targeted elimination of a single sugar moiety from a bacterial CPS.
Results

Antibody Response to GBS III-TT and V-TT Vaccines in Macaques.
The CPS-specific antibody response in healthy human adults (Table  S1 ) after a single dose of GBS type II or type III CPS conjugate vaccine was predominantly of the IgG subclass (19) (20) (21) . As a notable exception, the IgM-to-IgG ratio was 1.8-8.9 after receipt of a type V conjugate (22, 23) .
Studies to determine the underlying cause of this isotype pattern required an animal model mirroring human isotype responses. The rhesus macaque model was developed for this purpose. Female macaques were immunized with a single dose of III-TT or V-TT [both previously administered (19, 23) to healthy human adults]; Ϸ62% of total antibody measured at week 8 in sera from III-TT-vaccinated macaques was IgG, and Ϸ32% was IgM (Table 1 and Fig. 1A ). In contrast, only 18% of total antibody was IgG and 79% was IgM in 8-week sera from macaques given V-TT (Table 1 and Fig. 1B ). These isotype response patterns were similar to those in humans (Table S1) , with relatively high levels of IgM evoked by V-TT.
Epitope Specificity of IgG Elicited in Humans and Macaques by V-TT.
To study the epitope specificity of the immune response to type V CPSs, we used type V oligosaccharides and native type VII CPS. Type V oligosaccharides of 7.8 kDa or 6 RU were generated by ozone treatment of native type V CPS (204 kDa, 152 RU). Gentle acid hydrolysis of native type V CPS yielded dV CPS lacking the terminal sialic acid residue on each side chain (Fig. S1 ). Native GBS type VII CPS is a naturally occurring Values are expressed as the percentage of total immunoglobulin (IgA, IgG, IgM) quantitated. There were, on average, three rhesus macaques per vaccine group. variant of type V CPS (24) . Both have a trisaccharide side chain linked to the backbone glucose, but type VII lacks a side-chain glucose (Fig. S1 ). The structure of these CPSs was confirmed by anion-exchange chromatography and 1 H-NMR spectroscopy.
The epitope specificity of native V CPS-TT vaccine-induced antibody was determined by inhibition ELISA, with native type V CPS as coating antigen. The inhibitors were the natural and chemically modified CPSs shown in Fig. S1 and the 6-RU type V oligosaccharide. Serum from a healthy human adult recipient of V-TT recognized native type V CPS with 50% inhibition (IC 50 ) at 0.41 g/ml (Fig. 2B) . Binding of this serum was also inhibited by dV CPS (IC 50 , 0.24 g/ml). There was little difference between the ability of native type V CPS and the 6-RU oligosaccharide (IC 50 , 0.43 g/ml) to inhibit specific binding; no inhibition was measured with type VII CPS (Fig. 2B) .
Serum from a representative macaque given V-TT recognized dV CPS and native type V CPS, with a 3-fold difference between these CPSs in relative affinity (IC 50 , 0.57 and 1.82 g/ml, respectively) ( Fig. 2 A) . These antibodies recognized native type V CPS with higher specificity than they recognized the 6-RU polymer (IC 50 , 3.91 g/ml). No inhibition was measured with type VII CPS (Fig. 2 A) .
The dV-TT-induced IgG elicited in a representative macaque had CPS epitope-recognition patterns similar to those in humans and macaques after V-TT vaccination. The dV-TT antiserum recognized dV CPS with the highest relative affinity and also recognized native type V CPS (IC 50 , 0.01 and 0.27 g/ml, respectively) ( Fig. 2C ). Like V-TT macaque antiserum, dV-TT macaque antiserum had higher affinity (IC 50 , 0.27 g/ml) for the native (152-RU) than for the 6-RU type V polymer (IC 50 , 1.60 g/ml). Type VII CPS did not inhibit binding of dV-TT antiserum, even at 100 g/ml (Fig. 2C) .
Macaque Antibody Response to dV-TT. Epitope specificity studies indicated that a major epitope recognized by human and macaque sera probably resides in the trisaccharide backbone appended by the glucose side chain but also suggested that, in human sera, the dominant epitope on type V CPS is expressed after removal of the sialic acid residue located as the terminal moiety on the trisaccharide side chain. Thus, we prepared a conjugate with dV CPS.
At week 8, Ϸ58% of total antibody in sera from macaques given dV-TT was type V CPS-specific IgG, a 3-fold increase over the level of IgG obtained with V-TT (Table 1 and Fig. 1C ). The increase in IgG was concurrent with a decrease in IgM (Table 1 and Fig. 1C ). This result supports the hypothesis that the terminal sialic acid residue on the type V CPS side chain is critical for antigen recognition by the mammalian immune system.
Functional and Protective Capacity of dV-TT-Induced Macaque Anti-
sera. The ability of dV-TT-induced IgG and IgM purified from macaque antisera to opsonize GBS type V for killing by human peripheral-blood leukocytes was tested in an in vitro opsonophagocytosis and killing assay. Both IgG and IgM opsonized viable GBS in preparation for killing by effector cells, with a reduction of Ͼ1 log 10 in GBS cfu at antibody concentrations of 4.6 and 2.0 g/ml, respectively. A reduction of Ͻ0.1 log 10 was measured in the absence of antibody, complement, or effector cells. Macaque IgG and IgM (1 g/ml each) elicited by V-TT resulted in a reduction of Ͼ1 log 10 .
To confirm the functional capacity of dV-TT antisera, timedpregnant mice were given macaque immune sera during gestation, and newborn pups were challenged with an ordinarily lethal dose of viable GBS type V. Significant protection was afforded by passive immunization of mice with rhesus antisera. Twenty (67%) of 30 pups born to dams given dV-TT-immunized macaque antisera survived challenge (Table 2) , whereas only 3 (17%) of 18 pups born to dams given prevaccination macaque sera survived (P ϭ 0.001).
The survival rate among mice receiving rhesus dV-TT antisera was statistically similar to that among mice receiving rhesus V-TT antisera [25 (78%) of 32 challenged pups surviving; P ϭ 0.39] or human V-TT antisera [27 (73%) of 37 challenged pups surviving; P ϭ 0.60]. the survival rate was 38% (13 of 34) among challenged pups of dams that received saline with alum (P Ͻ 0.0001). The efficacy of dV-TT in mice was statistically similar (P ϭ 0.41) to that of V-TT (100%), the positive control (Table 2 ).
Structural Characterization of Native and Desialylated Type V CPS.
Structural determination of type V CPS (Fig. S1 ) was based partially on incomplete assignment of its 1 H-and 13 C-NMR signals (24) . Table S2 presents a more comprehensive assignment of these signals (with some reassignments) and their 1 H and 13 C chemical shifts.
Comparison of signals of native and desialylated type V CPSs reveals no significant differences in the chemical shifts of backbone residues (Fig. S1, residues A, E, F) ; the changes observed are within the range of experimental error (0.01 ppm for 1 H; 0.1 ppm for 13 C). The only significant chemical-shift changes on sialic acid removal from native CPS-those for branch ␤-D-Gal (residue G)-are due to direct sialic acid linkage effects (17, 24, 25) . NMR data for type V CPS were compared with chemical shifts published for some other GBS CPSs. In addition to linkage effects on the branched ␤-D-Gal residue, sialic acid removal from type III CPS has long-range effects on the CPS remote backbone Glc and GlcNAc residues, a finding that strongly suggests a conformational change (25, 26) . Comprehensive NMR (25) has shown that the protective epitopes are situated on extended helical segments of native type III CPS, which are probably formed by the proximity of its terminal sialic acid residues to backbone ␤-Glc residues. Type VII CPS also forms a conformational epitope, as indicated by similar chemicalshift changes in its backbone signals on removal of its terminal sialic acid residues (24), and its structure differs from that of type V (Fig. S1) 
only in that it lacks the branched terminal ␤-D-Glc residue (B) linked to O-3 of its backbone ␤-D-Gal residue (E).
Thus, one could conclude that the terminal ␤-D-Glc residue (B) of native type V CPS prevents its terminal sialic acid residues from interacting with its backbone ␤-D-Gal residue, with consequent conformational equivalence of the inner backbone residues of native and desialylated type V CPSs.
Discussion
CPS structure modifications have enhanced immunogenicity and have altered or eliminated epitopes that evoke antibodies crossreactive with host tissue (27, 28) . Several years ago, investigators substituted type 14 pneumococcal CPS for the structurally similar (29) GBS type III CPS in a vaccine. Both CPSs have a backbone trisaccharide linked to a galactose side chain; however, the galactose is the only and terminal sugar on the side chain in type 14 pneumococcal CPS, whereas a sialic acid residue is linked terminally on the side chain to the galactose in GBS III CPS. This sialic acid is essential for epitope specificity and induction of effective functional antibodies (30, 31) . NMR (25, 26) has shown that sialic acid removal from GBS III CPS induces significant chemical-shift changes even in the signals of its remote inner backbone residues. Backbone 13 C chemical-shift differences between native and desialylated type III CPS indicative of a conformational epitope have been described in ref. 25 . These differences were as large as 0.2-0.5 ppm, whereas differences in equivalent type V CPS backbone residues were within the range of experimental error (Ͻ 0.1 ppm). These chemical-shift differences in type III CPS indicate extensive conformational change within backbone residues. In contrast, sialic acid removal from type V CPS yields no significant chemical-shift changes in backbone residues (Table S2) ; this result constitutes evidence for the conformational equivalence and consequent immune equivalence of the backbone residues of native and desialylated type V CPSs.
The sudden emergence of GBS type V disease (32-37) prompted the development of a type V vaccine by the same technology used to create vaccines against types Ia, Ib, II, and III (38) . Although more immunogenic than uncoupled type V CPS, type V conjugates unexpectedly elicited more specific IgM than IgG (22) . A testable hypothesis is that the predominantly IgM response reflects host effector functions that recognize epitopes on type V CPS different from those recognized on other sialylated GBS CPSs. Our data suggest that few if any B cells in the human or the rhesus repertoire recognize the sialylated portion of type V CPS. The recognized epitopes include the trisaccharide backbone with the glucose side chain. Perhaps B cells recognizing the sialylated portion of type V CPS have been deleted from the repertoire because of structural similarities of this epitope to self-antigens.
Sialic acid moieties are found as terminal sugars on several types of mammalian tissues and on bacterial surfaces. Sialic acid on the GBS surface prevents activation of the alternative complement pathway (39) and is responsible for the conformational, helical structure of type III CPS (26) . We assessed whether the sialic acid of type V CPS is an essential component of the epitope responsible for the predominantly IgM response of humans to type V conjugates. Mice were not a suitable animal model because they respond to V-TT vaccination with a predominantly IgG response (data not shown). Rhesus macaques, in contrast, exhibit antibody isotype response patterns similar to those in humans. Inhibition studies showed that IgG elicited in both humans and macaques by native V-TT was specific to desialylated and native type V CPS. Despite great structural similarity, there was essentially no cross-reaction between type V-induced antibodies and type VII GBS CPS. This observation supported the high degree of antibody specificity to carbohydrates and the sufficiency of seemingly minor structural variances to yield antigenically distinct molecules.
A TT conjugate prepared with dV CPS induced isotype switching that resulted in a predominantly IgG response in macaques. This result differs from the human immune response to conjugates prepared with CPSs of types Ia, Ib, II, and III (Table S1 and data not shown) and strongly implicates the sialic acid residues of type V CPS in the unique response of human immune cells-even though all other CPS types have the same structural feature. A plausible explanation is a different presentation of sialic acid in type V CPS than in other CPS types. For example, protective IgG is induced by a conformational epitope situated on intermittent extended helical segments of type III CPS (40) ; the proximity of associated sialic acid residues to backbone residues (25) renders this CPS less accessible to direct interactions with the B cell receptor or other cellular receptors involved in signaling. Conversely, 1 H-and 13 C-NMR chemicalshift data for type V CPS (Table S2) are consistent with lack of a conformational epitope and of interactions between the CPS's *P ϭ 0.39 compared with V-TT sera; P ϭ 0.001 compared with preimmunization control sera. † P ϭ 0.41 compared with V-TT vaccine; P Ͻ 0.0001 compared with saline-alum. ‡ Human V-TT sera also resulted in 73% protection (27 of 37 pups survived). § Preimmunization macaque sera. ¶ Saline-alum.
terminal sialic acid and backbone residues. Under these circumstances, the sialic acid residue is conceivably more exposed and accessible on the molecule's periphery.
Although we cannot eliminate the possibility that the CPS: protein ratio of the type V conjugates influenced the macaque antibody response, clinical data suggest that this ratio is not the major cause of differences in IgG:IgM ratios. For example, five conjugate vaccines prepared with three GBS CPSs all had different CPS:protein ratios, yet the IgG response was proportionately higher for non-type V conjugates (Table S1 ).
Macaque IgG induced by dV-TT facilitated neutrophil killing of viable type V GBS in vitro; thus, we tested both antiserum functionality (passive immunity) and vaccine efficacy (active immunity) in mice. Passive administration of macaque dV-TTspecific antibodies to pregnant mice protected pups against challenge with a lethal dose of live type V. Active vaccination of female mice with dV-TT provided nearly complete protection to pups; this result unambiguously confirms the utility of this conjugate. The inclusion of a type V component in a multivalent GBS vaccine formulation is imperative, given the frequency of this serotype among invasive GBS isolates. A maternal vaccine must induce the highest achievable level of specific IgG to ensure protection of newborn infants. A strong maternal IgG response not only provides immediate protection to the newborn but also is durable and amenable to boosting. A dV CPS conjugate of the design described herein may prove a preferred approach to maximizing IgG.
Materials and Methods
GBS CPSs. CPSs of types III, V, and VII were isolated and purified from GBS strains M781, CJB111, and 7271, respectively, as described for type III (41) . The structure and purity of these CPSs and derivative type V oligosaccharides were verified by chemical techniques and 1 H-NMR spectroscopy.
Derivatives of Type V CPS. dV CPS was created by mild acid treatment of native type V CPS as described for type III (42) . Type V CPS (13 mg) was suspended in 1 ml of 3% acetic acid and heated at 80°C for 1 h. Acid-treated CPS was neutralized with sodium hydroxide, dialyzed against water, and lyophilized to dryness. Sialic acid loss was confirmed by analysis of a hydrolyzed sample on a chromatography system equipped with a PA1 column and pulse amperometric detector.
Oligosaccharides of type V CPS were generated by bubbling ozone (50 mg/h) into a solution of type V CPS suspended in PBS as described in ref. 43 . Aliquots were removed from the ozone generator at 120 min to obtain oligosaccharides of 7.8 kDa or 6 RU, which were purified by gel filtration chromatography, dialyzed, and lyophilized. Sizes of oligosaccharides were determined by elution on a Superose 6 or 12 column calibrated with dextrans of known molecular size.
GBS Conjugates. GBS conjugates were prepared by coupling native and chemically modified CPSs to monomeric TT (44) by reductive amination (41) . Before coupling, CPSs of types III and V were oxidized with periodate to create reactive aldehyde groups on 26 and 18% of the sialic acid residues, respectively, as determined by gas chromatography-mass spectrometry (41) .
For coupling to proteins, dV CPS was chemically oxidized by incubation with sodium periodate (0.1 mg per 1 mg of dV CPS) to create aldehyde groups on side-chain galactose residues. A dV CPS-TT (dV-TT) conjugate was prepared by mixing 4.1 mg of periodate-oxidized dV CPS with an equal amount of monomeric TT in 0.3 ml of 0.2 M sodium phosphate buffer (pH 7.2). Sodium cyanoborohydride (7.1 mg) was added, and reductive amination proceeded at 37°C for 4 days. Oxidized CPS is cross-linked at multiple sites to TT, which resulted in conjugates with molecular weights Ͼ10 6 . The conjugate was purified on a 16/50 Superose 6HR column in PBS. Column fractions containing high-molecular-weight material were pooled, and residual aldehydes were reduced by addition of sodium borohydride at pH 9 for 1 h. The mixture containing the conjugate was neutralized, dialyzed against water, and lyophilized to dryness. The dV-TT conjugate was composed of 38% (wt/wt) carbohydrate and 57% (wt/wt) protein. 
Immunogenicity in Macaques.
Nine female macaques (Macaca mulatta; 6-8 kg) of Indian origin were vaccinated s.c. with 50 g (as carbohydrate) of dV-TT, native V-TT, or III-TT (three animals each). Each vaccine was premixed in a 1:1 ratio with 1.3% Alhydrogel and delivered in a volume of 0.5 ml. Each animal was bled via the femoral vein before and weekly for 8 weeks after immunization. The macaques were anesthetized with ketamine HCl (10 -15 mg/kg, i.m.) before each immunization and serum withdrawal; they were weighed and given a complete physical examination each time they were anesthetized. Animals were housed in a specific pathogen-free barrier animal facility at New England Regional Primate Research Center, Harvard Medical School (Southborough, MA).
Efficacy in Mice.
The ability of GBS conjugate vaccines or vaccine-induced antisera to protect mice against GBS challenge was measured in the maternal immunization-neonatal mouse model as described in refs. 45 and 46. To evaluate the in vivo functional activity of macaque antisera, timed-pregnant CD-1 outbred mice (three dams per group) received an i.p. injection of 0.5 ml of antisera pooled from three primates immunized with native V-TT or dV-TT on gestation day 17. A 0.5-ml volume of either a standard human reference serum pool for type V (positive control; three dams) or pooled preimmunization sera from the six primates (negative control; two dams) was administered. The concentration of type V CPS-specific IgG administered was 10 -12 g/ml per dam. Pups were challenged 24 h after birth with 1.7-2.0 ϫ 10 5 cfu of GBS type V strain CJB111 (38-to 44-fold the determined LD 50). Survival was assessed after 48 h.
For active vaccination, female CD-1 outbred mice (10 weeks old; three to six per group) received two 2-g doses of V-TT or dV-TT as CPS admixed with 0.5 mg of alum in a total volume of 0.5 ml on days 0 and 21. Control dams (n ϭ 2) received 0.5 mg of alum diluted with normal saline in a volume of 0.5 ml. After the second dose, mice were mated and their offspring (Ͻ24 h of age) challenged i.p. with GBS type V strain CJB111 at 27 times the LD50 (1.2 ϫ 10 6 cfu). Survival was assessed after 48 h. Animals were handled and housed according to institutional and federal guidelines.
Quantitation, Epitope Specificity, and Functional Activity of Vaccine-Induced Antibody. CPS-specific antibody in human and macaque sera was measured by ELISA (20, 22) . Test sera were subjected to serial 2-fold dilution on 96-well microtiter plates coated with type V CPS covalently linked to human serum albumin (HSA), and binding of specific antibodies was detected with antihuman Ig alkaline phosphatase-labeled conjugates; specific human vaccineinduced standard serum pools were used to quantitate type V CPS IgG, IgA, and IgM. For ELISA of macaque sera, cross-reacting anti-human IgG, IgM, and IgA alkaline phosphatase-labeled conjugates were used.
Epitope specificity of macaque sera was assessed by inhibition ELISA, with native and chemically modified CPSs used as inhibitors (47) .
The ability of V-TT-and dV-TT-induced macaque antisera to opsonize GBS cells for killing by human peripheral-blood leukocytes was determined in an in vitro opsonophagocytosis assay (47) with type V strain CJB111 as the target. Results are expressed as the difference between the number of GBS cfu at the start of the experiment and that after 60 min of incubation.
NMR Spectroscopy. All spectra were determined in 2 H2O solutions at 40°C on a UNITY iNOVA 600-MHz instrument, with acetone (␦ H 2.225 and ␦C 31.05 ppm) as the internal reference. In clean TOCSY experiments, mixing times were 30, 60, and 100 ms. Statistics. Fisher's exact test was used to compare the efficacy of vaccines (InStat, version 2.0; GraphPad Software).
